静脉或骨内注射钙剂与生理盐水对院外心脏骤停成人自主循环恢复的影响:一项随机临床试验
这项双盲、安慰剂对照随机临床试验纳入397例院外心脏骤停成人,比较静脉或骨内注射氯化钙与生理盐水对持续自主循环恢复的影响。因中期分析提示钙剂组可能存在 harm,试验提前终止。钙剂组持续自主循环恢复37例(19%),生理盐水组53例(27%),风险比0.72(95%CI 0.49至1.03),差异无统计学显著(P=0.09)。
要点
- 钙剂组持续自主循环恢复19%,生理盐水组27%,风险比0.72(95%CI 0.49至1.03),P=0.09。
- 30天生存率钙剂组5.2%,生理盐水组9.1%,风险比0.57(95%CI 0.27至1.18),P=0.17。
- 30天良好神经功能结局钙剂组3.6%,生理盐水组7.6%,风险比0.48(95%CI 0.20至1.12),P=0.12。
核心结论
- 在院外心脏骤停成人中,与生理盐水相比,静脉或骨内注射钙剂未显著改善持续自主循环恢复。
- 这些结果不支持在院外心脏骤停成人中给予钙剂。
研究设计与样本
- 双盲、安慰剂对照随机临床试验,在丹麦中部地区开展,时间为2020年1月20日至2021年4月15日,末次90天随访为2021年7月15日。
- 纳入397例院外心脏骤停成人,随机分配至钙剂组(n=197)或生理盐水组(n=200);391例纳入分析(钙剂组193例,生理盐水组198例;平均年龄68岁[SD 14],女性114例[29%])。
- 干预为最多2次静脉或骨内注射5 mmol氯化钙或生理盐水,首剂在首剂肾上腺素后立即给予。
主要发现
- 基于383例患者的计划中期分析,指导委员会因担忧钙剂组 harm 而提前终止试验。
- 持续自主循环恢复:钙剂组37例(19%) vs 生理盐水组53例(27%),风险比0.72(95%CI 0.49至1.03),风险差-7.6%(95%CI -16%至0.8%),P=0.09。
- 30天生存:钙剂组10例(5.2%) vs 生理盐水组18例(9.1%),风险比0.57(95%CI 0.27至1.18),风险差-3.9%(95%CI -9.4%至1.3%),P=0.17。
- 30天良好神经功能结局(改良Rankin量表评分0-3):钙剂组7例(3.6%) vs 生理盐水组15例(7.6%),风险比0.48(95%CI 0.20至1.12),风险差-4.0%(95%CI -8.9%至0.7%),P=0.12。
- 在测量钙值且自主循环恢复的患者中,高钙血症钙剂组26例(74%) vs 生理盐水组1例(2%)。
临床怎么用
- 作者结论指出,这些结果不支持在院外心脏骤停成人中给予钙剂。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: It is unclear whether administration of calcium has a beneficial effect in patients with cardiac arrest. OBJECTIVE: To determine whether administration of calcium during out-of-hospital cardiac arrest improves return of spontaneous circulation in adults. DESIGN, SETTING, AND PARTICIPANTS: This double-blind, placebo-controlled randomized clinical trial included 397 adult patients with out-of-hospital cardiac arrest and was conducted in the Central Denmark Region between January 20, 2020, and April 15, 2021. The last 90-day follow-up was on July 15, 2021. INTERVENTIONS: The intervention consisted of up to 2 intravenous or intraosseous doses with 5 mmol of calcium chloride (n = 197) or saline (n = 200). The first dose was administered immediately after the first dose of epinephrine. MAIN OUTCOMES AND MEASURES: The primary outcome was sustained return of spontaneous circulation. The secondary outcomes included survival and a favorable neurological outcome (modified Rankin Scale score of 0-3) at 30 days and 90 days. RESULTS: Based on a planned interim analysis of 383 patients, the steering committee stopped the trial early due to concerns about harm in the calcium group. Of 397 adult patients randomized, 391 were included in the analyses (193 in the calcium group and 198 in the saline group; mean age, 68 [SD, 14] years; 114 [29%] were female). There was no loss to follow-up. There were 37 patients (19%) in the calcium group who had sustained return of spontaneous circulation compared with 53 patients (27%) in the saline group (risk ratio, 0.72 [95% CI, 0.49 to 1.03]; risk difference, -7.6% [95% CI, -16% to 0.8%]; P = .09). At 30 days, 10 patients (5.2%) in the calcium group and 18 patients (9.1%) in the saline group were alive (risk ratio, 0.57 [95% CI, 0.27 to 1.18]; risk difference, -3.9% [95% CI, -9.4% to 1.3%]; P = .17). A favorable neurological outcome at 30 days was observed in 7 patients (3.6%) in the calcium group and in 15 patients (7.6%) in the saline group (risk ratio, 0.48 [95% CI, 0.20 to 1.12]; risk difference, -4.0% [95% CI, -8.9% to 0.7%]; P = .12). Among the patients with calcium values measured who had return of spontaneous circulation, 26 (74%) in the calcium group and 1 (2%) in the saline group had hypercalcemia. CONCLUSIONS AND RELEVANCE: Among adults with out-of-hospital cardiac arrest, treatment with intravenous or intraosseous calcium compared with saline did not significantly improve sustained return of spontaneous circulation. These results do not support the administration of calcium during out-of-hospital cardiac arrest in adults. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04153435.
引用
- Vallentin MF, Granfeldt A, Meilandt C, et al. Effect of Intravenous or Intraosseous Calcium vs Saline on Return of Spontaneous Circulation in Adults With Out-of-Hospital Cardiac Arrest: A Randomized Clinical Trial. JAMA. 2021. PMID: 34847226. doi:10.1001/jama.2021.20929
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。